SkyRX review

SkyRX's two semaglutide forms and named care partners make it a substantive option to compare. The annual prepayment condition, uncertain final charge and unclear treatment of unused prepaid months are decisive questions before purchase.

SkyRX is a prescription platform whose terms identify Viking Man Inc. as the operator. The terms list several Metamorphosis Aesthetics medical-group entities and a network of pharmacies, including PharmXpress, Health Warehouse, BPI Labs and Precision Compounding. The listing does not identify the group or pharmacy assigned to an individual prescription. One pharmacy's own public page corroborates its corporate connection with the operator, but that is not independent verification of any particular fill.

A health-history review by a clinician precedes prescribing. The general FAQ describes a typical review target and a prior physician-visit condition; these are provider-stated process requirements, not a guaranteed approval time or proof of eligibility.

The weight-loss page lists compounded semaglutide injection and oral-drop products. The FAQ describes the non-injectable form as sublingual. The same page marks tirzepatide injection and oral cards coming soon. A generic FAQ reference to tirzepatide does not make those cards presently available.

State access is product-specific. The weight-loss FAQ says GLP-1s are not available in all fifty states. A broader FAQ roster for the platform is not a verified GLP-1 service map. The terms prohibit use by minors. Confirm the prescribed form and state before planning a purchase.

The product page and general FAQ give differing shipping cutoffs and handling schedules. Those published windows should not be treated as a guaranteed next-day arrival for a particular prescription. The FAQ says shipments may be monthly or quarterly and might be switched to on-demand after a first order, while general terms discuss automatic renewal. Ask how this works for the selected annual offer.

The semaglutide injection and drop cards show a $199 monthly equivalent only with a twelve-month subscription paid upfront in full. Multiplying the display yields $2,388 before unestablished taxes, fees or product-specific variation. That is arithmetic, not a confirmed final checkout charge or a $199 monthly debit. SkyRX says actual price depends on the product and plan.

Its general terms also describe monthly auto-renewing products, with possible renewal and dispatch before the nominal date. They do not reconcile the advertised annual prepayment with a specific refill quantity, annual renewal charge or refund for unused months. The FAQ's monthly or quarterly shipment language does not establish twelve monthly boxes. Get the full initial charge, supply plan, refill schedule and following-year terms in writing.

Marketing says no contracts and cancel anytime; the terms require cancellation at least two days before renewal and reject partial-period refunds. A possible reactivation charge is described after cancellation. The return page says prescription sales are final. The FAQ describes a full refund if a clinician finds someone unsuitable; terms separately describe a conditional four-month medication-cost guarantee for qualifying new customers who follow prescribed weekly dosing and documentation rules. That guarantee should not be assumed to cover oral drops or an unused annual balance. Its evidence and timing rules are restrictive, so ask which remedy applies to your exact plan.

The injection and sublingual-drop semaglutide listings are compounded prescriptions, not FDA-approved versions of branded semaglutide. The 2.5 mL shown on each card is container volume, not a prescribed dose or proof of a month's supply. Strength, concentration, additives and patient instructions are not established by that label.

Tirzepatide cards remain marked coming soon. The selected pharmacy, dosage form, actual supply and state eligibility must be confirmed for any prescription. Do not infer product equivalence or a treatment outcome from marketing statements about the molecule.